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REPLY
We appreciate the suggestions of Dr. Veyrat regarding our study
(1) and agree that it would be of interest to trigger the computed
tomographic (CT) images at the time point of maximal aortic valve
opening as previously calculated with Doppler velocity-time inte-
gral. However, some technical and logistic considerations arising
from the CT perspective should be taken into account.
The heart rate may be significantly different between the
transthoracic echocardiography (TTE) and the CT examination.
Frequently, the heart rate increases during contrast agent injection,
which is performed immediately before the scan. Therefore, the
maximal aortic valve opening cannot be expected to be at the same
time point.
Therefore, we chose an “empiric” approach to identify the
maximal aortic valve opening. We reconstructed the aortic valve at
multiple time points throughout the systole and identified the
maximal valve opening based on visibility. Considering a mean
duration of the QRS complex of 80 ms (a QRS complex of 120 ms
or longer is regarded as bundle branch block), we started the image
reconstruction series 50 ms after the beginning of the QRS so as
to begin early enough and not miss the valve opening. We would
like to emphasize that Figure 1 in our report should illustrate the
CT image reconstruction algorithm and not regular cardiac elec-
trophysiology.
In clinical practice, we perform planimetry of the aortic valve
area (AVA) mainly in outpatients who are referred to coronary
CT-angiography for suspected coronary artery disease and in
whom previously unknown aortic valve calcification is present in
order to select patients with aortic stenosis and with nonstenotic
aortic valve sclerosis. The patients are then re-evaluated with TTE
if aortic stenosis is identified. Therefore, a TTE examination
before the CT-angiography in each patient would be logistically
difficult to organize. Additionally, many patients show valve
calcification, but only a minority presents with aortic stenosis.
Coronary CT-angiography is currently being increasingly per-
formed in our institution, but the use of CT as an alternative
imaging modality, if TTE is inadequate, is extremly rare.
Finally, currently we are using 64-slice CT technology, which
has improved planimetry of the AVA in terms of better image
quality at higher heart rates and a reduction of the postprocessing
time. We perform on average 4 to 8 cardiac CT scans daily, and in
our experience, 12% of the cardiac cycle is an appropriate time
point for CT image reconstruction in the majority of patients.
However, the dynamics of the aortic valve have to be reviewed
previously using 4-dimensional display (e.g., using the INSPACE
4-D software, Syngo Heart View, Siemens) because maximal aortic
valve opening may range between 5% (2) and 20% of the RR-interval.
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Percutaneous Laser
Revascularization Does Not Equal
Transmyocardial Laser Revascularization
The recent results of a trial of percutaneous laser revascularization
(PMR) (1) are noteworthy for their confirmation that this tech-
nique does not appear valid; however, these findings cannot be
extrapolated to other forms of laser therapy. Although Leon et al.
(1) are to be congratulated for performing this study, they have also
peformed a significant disservice by equating results from a 3- or
4-mm subendocardial laser divot placed under remote control
using an unapproved laser device with results documented in
thousands of patients with a Federal Drug Administration-
approved laser in which channels are placed under direct vision and
treat the full thickness of the myocardium as is performed with
surgical transmyocardial laser revascularization (TMR). The re-
searchers dismissed the TMR results as being largely placebo
because their results with PMR were equivalent with a placebo
group. Whereas the placebo effect plays a role in any treatment, to
dismiss objective data, including improved perfusion as noted by
single-photon emission computed tomography (SPECT) and
positron emission tomography (PET) scanning, and improved
function as noted by echocardiography and magnetic resonance
imaging (MRI) (seen with TMR), is wrong. Such improvements
cannot be willed by the patient regardless of the strength of the
placebo. The symptomatic benefits seen with TMR have lasted
longer in more patients than has ever been seen from any placebo.
Furthermore, to equate surgical TMR with internal mammary
artery ligation is unfair at best. In addition to severe angina, all of the
TMR patients had angiographic evidence and objective demonstra-
tion of malperfusion. It is not known whether the patients who
underwent mammary artery ligation even had coronary artery disease.
The primary conclusion that can be drawn from this study is that
PMR does not work. To extrapolate that to other laser techniques is
akin to stating that, like calcium channel blockers, beta-blockers are
ineffectual after a myocardial infarction because both are “blockers.”
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